Table 1.

Outcome measures of the trial

Outcome measures		Measurement method	Time frame
Primary outcome measure
1A	Plasmodium spp. infection diagnosed by RDT [Change in the prevalence of Plasmodium spp. infections detected by RDT per week per village]	RDT	Assessed weekly, longitudinally over 12 months
Secondary outcome measures
2A	Symptomatic malaria diagnosed by RDT [Change in the prevalence of symptomatic Plasmodium spp. infections detected by RDT per week per village]	RDT and Malaria register	Assessed weekly, longitudinally over 12 months
2B	Plasmodium spp. infection as determined by polymerase chain reaction (PCR) [Change in the prevalence of Plasmodium spp. infection as determined by PCR from RDT cassette samples and dried blood spot (DBS) samples]	PCR	Assessed weekly, longitudinally over 12 months
2C	Plasmodium spp. infections with drug resistance mutations [Change in the prevalence of Plasmodium spp. infection with drug resistance mutations]	PCR	Assessed weekly, longitudinally over 12 months
2D	Prevalence of antibodies to Plasmodium spp. [Prevalence of antibodies to Plasmodium spp. determined by Enzyme Linked Immunosorbent assay (ELISA) from RDT and DBS samples]	ELISA	Assessed weekly, longitudinally over 12 months
2E	Levels of antibodies to Plasmodium spp. [Levels of antibodies to Plasmodium spp. determined by Enzyme Linked Immunosorbent assay (ELISA) from RDT and DBS samples]	ELISA	Assessed weekly, longitudinally over 12 months
2F	Prevalence of antibodies to vector salivary antigens [Levels of antibody biomarkers of vector exposure]	ELISA	Assessed weekly, longitudinally over 12 months
2G	Levels of antibodies to vector salivary antigens [Levels of antibody biomarkers of vector exposure]	ELISA	Assessed weekly, longitudinally over 12 months